Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease

Dateline City: 

WHITEHOUSE STATION, N.J. & AUSTIN, Texas

Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck’s Lead Investigational Medicine for Alzheimer’s Disease

WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and
license agreement to develop a companion diagnostic device that will be
evaluated to help screen patients for recruitment into Merck's clinical
development program for MK-8931, a novel oral beta amyloid precursor
protein site cleaving enzyme (BACE) inhibitor and Merck's lead
investigational candidate for Alzheimer's disease (AD).
Language: 

English

Contact HTML: 

Media Contacts:MerckCaroline Lappetito, 267-305-7639orLuminexMimi Torrington, [e-mail] Contacts:MerckCarol Ferguson, 908-423-4465orLuminexMatt Scalo, [e-mail]

Ticker Slug: 

Ticker: MRK Exchange: NYSE
...

Source: Merck.com - Research and Development News - March 13, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news